Neurotrophin-3 therapy for Charcot–Marie–Tooth disease type 1A
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Charcot–Marie–Tooth disease type 1A (CMT1A), a common inherited peripheral neuropathy (estimated prevalence 1 in 7,000 to 8,000), is caused by intrachromosomal duplication of a 1.4-megabase segment of chromosome 17p12. This large segment of duplicated DNA contains more than 20 genes, for each of which CMT1A patients have three copies, rather than the normal two.1 However, the excess copy number of only one of these genes, peripheral myelin protein 22 (PMP22), seems to be responsible for all of the phenotypic features of CMT1A. Thus, rodents engineered to express multiple additional copies of the PMP22 gene, and hence to synthesize excess amounts of PMP22 protein, develop widespread peripheral nervous system (PNS) segmental demyelination and distal PNS sensorimotor axonopathy closely resembling the PNS pathology seen in patients with CMT1A.2 PMP22 is a Schwann cell transplasma membrane protein that, by virtue of adhesive interactions with the principal myelin glycoprotein, P0, contributes to the organization and stabilization of compact myelin.3 Important recent evidence in support of a cause-and-effect relationship between excess PMP22 protein expression in CMT1A was provided by …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.